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Introduction: Over the past decade, obesity has become a risk factor for developing chronic
kidney disease. Proteinuria is known to be an independent determinant of the progres-
sion  of chronic kidney disease, and adipose tissue is a recognized source of components of
the  renin–angiotensin–aldosterone system (RAAS). Recent studies have shown that plasma
aldosterone levels are disproportionately higher in patients with obesity. Drugs that block
the  RAAS are unable to inhibit aldosterone in the long term. The aim of our study was  to
analyze the renoprotective effect of an aldosterone antagonist in combination with RAAS
blockers in patients with obesity and proteinuric nephropathy.
Material and methods: This study is a substudy of previously published study on the
renoprotective effect of mineralocorticoid receptor blockers in patients with proteinuric
nephropathies. Patients with proteinuria levels >1 g/24 h who were taking spironolactone
and were being treated with other RAAS blockers were divided according to body mass
index (BMI) into an obesity group (BMI ≥30 kg/m2) and a control group.
Results: Seventy-one patients were included in the study, with a mean age of 56.7 ±
15.1  years. More than 50% of the patients in both groups had diabetes. Thirty-two patients
were included in the obesity group and 39 were included in the control group. There were no
signiﬁcant differences in renal function, proteinuria, blood pressure, serum potassium levels
and the percentage of RAAS blockers in both groups. After a follow-up of 28.9 (14–84) months,
there was a 59.4% reduction in proteinuria in the obesity group (2.8 ± 2.1 vs. 1.3 ± 1.6 g/24 h,
p  < .05). The reduction in proteinuria was greater than 50% in 22 (68.8%) cases, and the mean
blood pressure showed a signiﬁcant decrease (from 100.6 ± 9 to 92.1 ± 7.4 mm Hg, p < .05).
The control group showed a 69.6% reduction in proteinuria (1.9 ± 1.4 to 0.8 ± 0.5,ion of proteinuria was higher than 50% in 22 (68.8%) cases in obesep  < 0.05). The reductpatients and in 33 (84.6%) cases in non-obese group. Renal function remained stable in
both groups during the follow-up. Nine patients (28.1%) in the obesity group experienced
gynecomastia. The incidence of hyperkalemia was similar for the 2 groups (6.3%).
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Conclusion: Aldosterone antagonist treatment in obese patients with proteinuric
nephropathies induces a drastic and sustained reduction in proteinuria but not more  than
the  non-obese group. There was a trend toward slowing progression of renal failure with
few adverse events.
© 2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Efecto  beneﬁcioso  a  largo  plazo  de  la  incorporación  de  un  antagonista
de  la  aldosterona  a  un  tradicional  bloqueo  del  sistema
renina-angiotensina-aldosterona  en  pacientes  con  obesidad  y  proteinuria
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Introducción: Durante la última década, la obesidad se ha convertido en un factor de
riesgo para el desarrollo de la enfermedad renal crónica. La proteinuria está conside-
rada un factor independiente de la progresión de la enfermedad renal crónica y el tejido
adiposo se reconoce como una fuente de los componentes del sistema renina-angiotensina-
aldosterona (SRAA). Estudios recientes han demostrado que los niveles de aldosterona
plasmática son desproporcionadamente mayores en pacientes con obesidad. Los fármacos
que bloquean el SRAA son incapaces de inhibir la aldosterona a largo plazo. El objetivo de
nuestro estudio fue analizar el efecto protector a nivel renal de un antagonista de la aldos-
terona en combinación con bloqueadores del SRAA en pacientes con obesidad y nefropatía
con  proteinuria.
Material y métodos: Este estudio es un subestudio del estudio publicado previamente sobre
el  efecto protector a nivel renal de los bloqueadores del receptor de mineralocorticoides en
pacientes con nefropatías con proteinuria. Se dividió a los pacientes con niveles de prote-
inuria >1 g/24 h que estaban tomando espironolactona y se los trataba con otros blo-
queadores del SRAA según el índice de masa corporal (IMC) en un grupo de obesidad (IMC
≥30 kg/m2) y un grupo de control.
Resultados: Se incluyó a 71 pacientes en el estudio, con una media de edad de 56,7 ±
15,1 an˜os. Más del 50% de los pacientes en ambos grupos tenía diabetes. Se incluyó a
32  pacientes en el grupo de obesidad y a 39 en el grupo de control. No hubo diferen-
cias  signiﬁcativas en la función renal, proteinuria, presión arterial, niveles de potasio
sérico  y el porcentaje de bloqueadores del SRAA en ambos grupos. Tras un seguimiento de
28,9 meses (14-84), hubo una reducción del 59,4% de la proteinuria en el grupo de obesidad
(2,8 ± 2,1 frente a 1,3 ± 1,6 g/24 h, p < 0,05). La reducción de la proteinuria fue superior al
50% en 22 casos (68,8%) y la presión arterial media experimentó una disminución signiﬁca-
tiva  (de 100,6 ± 9 a 92,1 ± 7,4 mm Hg, p < 0,05). El grupo de control experimentó una reducción
del 69,6% de la proteinuria (de 1,9 ± 1,4 a 0,8 ± 0,5, p < 0,05). La reducción de la proteinuria fue
superior al 50% en 22 casos (68,8%) en pacientes obesos y en 33 casos (84,6%) en el grupo de
no  obesos. La función renal de ambos grupos permaneció estable durante el seguimiento.
En  9 pacientes (28,1%) del grupo de obesidad se observó ginecomastia. La incidencia de
hiperpotasemia fue similar en los 2 grupos (6,3%).
Conclusión: El tratamiento con un antagonista de la aldosterona en pacientes obesos con
nefropatías con proteinuria induce una reducción drástica y sostenida de la proteinuria,
pero no superior a la del grupo de no obesos. La tendencia fue frenar la progresión de la
insuﬁciencia renal con pocos eventos adversos.
©  2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-ND
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besity is a known cause of proteinuria and progressive renal
amage.1–3 Recent studies have shown that glomerulopathy
ssociated with obesity is an increasingly diagnosed condi-
ion and has a greater incidence.3,4 Furthermore, obesity has(http://creativecommons.org/licenses/by-nc-nd/4.0/).
been shown to participate in the progression of various kid-
ney diseases.5–7 Higher levels of proteinuria are a signiﬁcant
risk factor in the progression of kidney disease in patients
with diabetic and nondiabetic nephropathy. Any therapeutic
measure that reduces proteinuria will have a positive renopro-
tective effect on the long-term outcome of renal function.8,9
The most effective antiproteinuric measures among these
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therapies are a renin–angiotensin–aldosterone system (RAAS)
blockade in its various modalities, angiotensin-converting
enzyme inhibitors (ACEIs), angiotensin-receptor antagonists
(ARAs) and, more  recently, aldosterone antagonists (AAs).10,11
Considering the above, as well as the role of obesity in the
progression of kidney diseases and the epidemic proportions
that obesity has reached in developed societies, the response
of patients with obesity and proteinuric nephropathy to the
various strategies that block RAAS is a topic of extraordinary
clinical importance, considering that RAAS activity is greater
in obesity.12,13 Although the initials data on the antipro-
teinuric response of ACEIs or ARAs in obese patients were
contradictory, recently the post hoc analysis of the Ramipril
Efﬁcacy in Nephropathy (REIN) trial indicated that the risk
reduction for renal disease progression to end-stage-renal-
diseases (ESRD) and the antiproteinuric effect by ramipril was
more  pronounced in obese population.14 Current studies sug-
gest that patients with obesity have increased aldosterone
synthesis, which could play an important role in the var-
ious complications associated with obesity, including renal
damage.15,16 Experimental studies conducted with obese ani-
mals have shown that the use of AAs drastically reduces renal
lesion progression.17,18 This research suggests that patients
with obesity and proteinuric nephropathy could have a more
favorable antiproteinuric response to AAs than to traditional
RAAS blockage with ACEIs or ARAs. However, there is little
information in the literature on the role of AAs in the protein-
uria of patients with obesity.19,20
There is little information regarding the antiproteinuric
effect of AA alone or combined with RAAS blockade long
term obese patients with proteinuric nephropathies. In the
scientiﬁc community there is growing concern about the new
epidemic of the XXI century, the obesity. The aim of this study
was analyze how obese patients responded to treatment with
AA compared with non-obese patients.
In 2004, a clinical protocol was started based on the
addition of spironolactone to patients with proteinuric
nephropathy who  maintained proteinuria levels >1 g/day,
despite treatment with ACEIs or ARAs.21 This study is a sub-
study that analyzes (a) the antiproteinuric effect over time of
AAs on patients with obesity and (b) whether treatment with
spironolactone slows the progression of renal failure in this
patient group.
Material  and  methods
Patients
In January 2004, we  began a prospective cohort study based on
the addition of spironolactone to patients who had persistent
proteinuria levels >1 g/24 h, despite the maximum tolerated
dosages of ACEIs, ARAs or their combination for more  than
6 months regardless of the etiology of renal disease. There
were no restrictions based on age or renal function. We
excluded patients with the same criteria as in the previous
21study. This substudy excluded those patients with follow-
up less than 12 months for various reasons. In the obese
group were excluded 6 patients, 2 for follow-up less than
3 months, 2 patients had developed a deterioration of renalFig. 1 – Flow-chart of patients in the overall group.
function in the ﬁrst month after AA treatment and 2 patients
for hyperkalemia uncontrolled in the ﬁrst month after AA
treatment. In the control group 10 patients were excluded, 5
for follow-up less than 3 months, 1 patient had developed an
acute deterioration of renal function and 4 patients developed
hyperkalemia after AA treatment (Fig. 1).
Seventy-one patients were included in this protocol. We
established 2 patient groups according to body mass index
(BMI): an obesity group for patients with a BMI  ≥ 30 kg/m2 and
a control group for patients with a BMI < 30 kg/m2. The study
was approved by the Hospital’s Ethics Committee.
Therapeutic  intervention
Spironolactone was added at a dosage of 25 mg/day to the
baseline therapy of all patients. During the follow-up, the
spironolactone dosage was adjusted according to measure-
ments of blood pressure (BP) or serum potassium levels. For
a number of the patients who had an insufﬁcient antiprotein-
uric response (<30% of baseline values) but had good tolerance,
the dosage was increased to 50 mg/day. For the patients
who experienced adverse effects other than hyperpotassemia
(mainly gynecomastia), spironolactone was replaced with
eplerenone at a dosage of 25 mg/day. The baseline dosages
of ACEIs, ARAs or both were not modiﬁed at the start of the
study. The dosages were subsequently modiﬁed for a number
of patients based on measurements of BP and serum potas-
sium levels. For a number of the patients with antiproteinuric
responses >30% of baseline values and a difﬁcult management
of serum potassium levels, the ACEI and/or ARA-2 dosages
were progressively lowered or, in a number of cases, had
to be discontinued. For proper control of serum potassium
levels, we recommended the same measures as in the previ-
ous study.21 The BP objective was established at levels below
130/80 mm Hg.
Follow-up  and  data  collection
All patients were treated in outpatient clinics after 1 month
of treatment with spironolactone. These data were collected
as in the previous study.21 The mean follow-up was 28.9 ± 14
(14–84) months.
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Table 1 – Demographic, clinical and analytical characteristics at baseline of the overall patient group treated with AA
(n = 71), the obesity group (N = 32) and control group (N = 39).
Variable Total group (n = 71) Patients with obesity (n = 32) Patients with no obesity (n = 39) P value
Age, years 56.7 ± 15.1 (22–79) 61.8 ± 11.3 (34–79) 52.5 ± 16.6 (22–79) 0.01
Sex, M/F 46/25 21/11 25/14 0.89
SCr, mg/dL 1.4 ± 0.6 (0.4–3.4) 1.4 ± 0.5 (0.5–2.6) 1.3 ± 0.7 (0.4–3.4) 0.64
eGFR, ml/min/1.73 m2 64.3 ± 36.3 (19.2–212) 56.9 ± 27 (24.9–138.2) 70.5 ± 41.8 (19.1–212) 0.11
Proteinuria, g/24 h 3  ± 2.1 (1–10.4) 2.8 ± 2.1 (1–10.3) 3.2 ± 2.1 (1–10.4) 0.41
MAP, mm Hg 99.6 ± 10.9 (68.3–125.3) 100.6 ± 9 (88.3–120) 98.8 ± 12.2 (68.3–125.3) 0.49
Serum potassium, mEq/L 4.6 ± 0.5 (3.5–5.7) 4.7 ± 0.3 (3.7–5.3) 4.5 ± 0.5 (3.8–5.7) 0.18
BMI, kg/m2 29.4 ± 4.5 (21.6–42.5) 33.3 ± 3.2 (30–42.4) 26.2 ± 2.4 (21.6–29.9) 0.00
Treatment (%)
• ACEI 15 (21.1) 8 (25) 7 (17.9) 0.46
• ARA 37 (52.1) 15 (46.9) 22 (56.4) 0.42
• ACEI+ARA 19 (26.8) 9 (28.1) 10 (25.6) 0.81
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARA, angiotensin-receptor antagonist; BMI, body mass index; eGFR, estimated
glomerular ﬁltration rate; F, female; M, male; MAP, mean arterial pressure; SCr, serum creatinine. Numbers in brackets correspond to ranges,
except for the “Treatment” variable, where they correspond to percentages.
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tudy  objectives
he primary study objective was to compare the reduction in
roteinuria in the obesity group at the end of the follow-up
ompared with the control group. We analyzed the number
f patients who  achieved a >50% reduction in proteinuria
rom baseline values during their follow-up. The secondary
bjectives included comparing the change in the glomeru-
ar ﬁltration rate (GFR) during the 12-month period prior to
pironolactone treatment compared with the period between
aseline and the end of the follow-up and the period
etween the ﬁrst month following treatment and the end of
ollow-up. The change in GFR was measured in mL/min/year.
he response to AA treatment was analyzed separately for the
besity and control groups. We  also analyzed the tolerance to
pironolactone and its adverse effects.
eﬁnitions
he follow-up period was calculated with the same criteria as
n the previous study.21 Renal function was measured by GFR
sing the simpliﬁed 4-variable Modiﬁcation of Diet in Renal
isease formula (MDRD-4). BMI  was measured as weight in
ilograms divided by the height squared in meters. Mean arte-
ial pressure (MAP) was calculated as the sum of the diastolic
lood pressure and one third of the pulse pressure. To calculate
he improvement in the loss of GFR, we established a cutoff
or the mean value of the GFR slope in the ﬁrst 12 months prior
o treatment (−3 mL/min/year), considering that the patients
ho  managed to reduce this loss of GFR from the start of treat-
ent to the end of follow-up were categorized as patients who
chieved an improvement in renal function.
tatistical  analysishe data are expressed as mean ± standard deviation (SD)
r median and interquartile range for continuous normal
nd non-normal variables, respectively. The continuous vari-
bles with normal distribution are expressed as mean and4; for glomerular ﬁltration rate (mL/min/1.73 m2, multiply by 0.0167;
SD, while the noncontinuous variables are expressed as medi-
ans, 25 and 75 percentiles and interquartile range. Categorical
variables are expressed as frequencies and percentages. The
Spearman correlation test, paired t tests and Wilcoxon test
were employed for the analysis of continuous variables when
indicated. Differences between the qualitative variables were
compared using the chi-squared test. For all tests, values of
p < .05 were considered statistically signiﬁcant. The data were
assessed with the SPSS program, version 15.0 for Windows
(SPSS, Chicago, IL, USA).
Results
Patient  characteristics
Seventy-one patients were included in the protocol with
spironolactone. Their demographic, clinical and laboratory
test characteristics at the start of the study are shown in
Table 1. The number of patients who were treated with antihy-
pertensive drugs other than RAAS blockers at the start and end
of the follow-up was as follows: calcium-antagonists, 8 (11%)
and 6 (8%), respectively; beta-blockers, 6 (8%) and 6 (8%); and
alpha blockers, 5 (7%) and 4 (6%). Before starting treatment
with an AA, 15 (21%) patients were treated with an ACEI, 37
(52%) were treated with an ARA and 19 (27%) were treated with
a combination of an ACEI and ARA. Forty-ﬁve patients were
treated with ARA+AA, 20 patients were treated with ACEI+AA
and 4 were treated with ACEI+ARA+AA at the end of the follow-
up, while 2 patients were treated with an AA alone. In Table 1,
we can observe the main differences between the 2 study
groups.
ProteinuriaIn the obesity group, we observed a signiﬁcant reduction in
proteinuria from the ﬁrst month of treatment with spirono-
lactone (2.8 ± 2.1 to 1.8 ± 1.8 g/day, p < .05, which represents
a 46.3% reduction [range 26.9–58.4] from baseline values).
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Table 2 – Evolution of the main clinical and analytical factors before and after treatment with AA in the obesity group
with ACEI (n = 32) and the control group (n = 39) at baseline.
Variable −12 m Baseline +1 m (n = 32/39) +12 m (n = 32/39) +24 m (n = 29/33) +36 m (n = 19/17) +48 m (n = 7/9) Last visit
SCr, mg/dL
Obesity 1.3 ± 0.4 1.4 ± 0.5** 1.5 ± 0.4 1.5 ± 0.4* 1.5 ± 0.5* 1.5 ± 0.6* 1.4 ± 0.6 1.5 ± 0.5*
Control 1.3 ± 0.6 1.3 ± 0.6 1.5 ± 0.7* 1.6 ± 0.8* 1.5 ± 0.7* 1.4 ± 0.7* 1.4 ± 0.7 1.5 ± 0.7*
eGFR, mL/min/1.73 m2
Obesity 60.9 ± 28.3 56.8 ± 27** 53.5 ± 26.9 49.9 ± 20.8* 54.4 ± 32.1 60.3 ± 36.9 64.1 ± 38.5 54.1 ± 30.9
Control 76.6 ± 51.7 70.5 ± 41.8 63.5 ± 36.7* 60.7 ± 43.5* 65.6 ± 48* 76.3 ± 57.3 76.4 ± 39.9 65.4 ± 45.9*
Serum Potassium, mEq/L
Obesity 4.6 ± 0.4 4.7 ± 0.3 5 ± 0.4* 5 ± 0.5* 4.9 ± 0.4* 4.8 ± 0.5 4.7 ± 0.4 4.9 ± 0.5*
Control 4.6 ± 0.5 4.5 ± 0.4 4.9 ± 0.6* 4.9 ± 0.5* 4.8 ± 0.5* 4.7 ± 0.5 4.7 ± 0.5 4.8 ± 0.5*
Proteinuria, g/24 h
Obesity 2.2 ± 2.5 2.8 ± 2.1 1.8 ± 1.8* 1.2 ± 1.7* 1.4 ± 1.7* 1.6 ± 2.1* 1.3 ± 1.1* 1.3 ± 1.6*
Control 1.9 ± 1.4 3.2 ± 2.1** 1.9 ± 1.2* 1.2 ± 0.9* 0.8 ± 0.6* 0.8 ± 0.6* 1 ± 0.6* 0.8 ± 0.5*
Reduction in proteinuria from baseline, %
Obesity 46.3 (26.9–58.4) 65 (48.7–82.8) 54.7 (38.4–72.5) 60.7 (33.5–75.2) 50.8 (33.5–64) 59.4 (43.2–73)+
Control 41.8 (23.1–51.1) 63 (25.1–78.9) 69.6 (56.2–87.1) 69.7 (56.2–88.2) 69.4 (49.3–91) 69.6 (57.4–82.8)
BMI, kg/m2
Obesity 33.3 ± 3.4+ 33.3 ± 3.2+ 32.6 ± 2.8+ 32.8 ± 3.7+ 32.9 ± 3.2+ 32.4 ± 2.8+ 33.6 ± 3.9+ 33.3 ± 3.8+
Control 26.1 ± 2.5 26.2 ± 2.4 26.4 ± 2.5 26.4 ± 2.8 26.3 ± 3.1 26.6 ± 3.4 26.6 ± 4.1 26.3 ± 3
MAP, mm Hg
Obesity 97 ± 8.8 100.6 ± 9** 93.2 ± 10.8* 91.6 ± 7.3* 91.9 ± 7.5* 91.6 ± 6.7* 90.2 ± 5.4 92.1 ± 7.4*
Control 98.9 ± 13.3 98.8 ± 12.2 95.4 ± 10.4* 96.5 ± 11.7 92.3 ± 11.3* 91.5 ± 13.4* 88.2 ± 12.7* 92.2 ± 10.7*
Abbreviations: eGFR, estimated glomerular ﬁltration rate; MAP, mean arterial pressure; SCr, serum creatinine.
∗ p < .05 with respect to baseline.∗∗ p < .05 with respect to −12 month.
+ p < .05 between groups.
The mean reduction in proteinuria was maintained in 65%
of the patients (range 48.7–82.8) at 12 months, with no ten-
dency toward reduction during the follow-up (Tables 2 and 3
and Figs. 2 and 3). At the end of the follow-up, the pro-
teinuria levels were 1.3 ± 1.6 g/day (p < .0001 compared with
baseline proteinuria), which represents a 59% reduction (range
43–73%) when compared with baseline values. A shown in
Fig. 3, most patients of obesity group achieved reductions of
more  than 50% in proteinuria from baseline values, and this
reduction was maintained over the course of the follow-up
(72% of patients at month 12, 65.5% at month 24, 63.2% at
month 36, 57.1% at month 48 and 68.8% of at the end of
follow-up). There was no correlation between the changes
in GFR and the changes in proteinuria (r = 0.27, p = .12) or
between the changes in blood pressure and the reduction in
Table 3 – Outcome of a number of characteristics in both group
Variable Patients with obesity (n =
Patients with diabetes, n (%) 16 (50) 
Reduction in proteinuria >30%, n (%) 27 (84.4) 
Reduction in proteinuria >50%, n (%) 22 (68.8) 
Renal function stabilization, n (%) 20 (62.5) 
Gynecomastia, n (%) 9 (28.1) 
Change in spironolactone, n (%) 9 (28.1) 
Hyperpotassemia, n (%) 2 (6.3) 
Treatment, n (%)
• ACEI+AA 10 (31.3) 
• ARA+AA 21 (65.6) 
• ACEI+ARA+AA 0 (0) 
• AA 1  (3.1) 
Abbreviations: AA, aldosterone antagonists; ACEI, angiotensin-convertingproteinuria (r = 0.24, p = .19). In the control group, the mean
reduction in proteinuria was maintained in 63% of the patients
(range 25.1–78.9) at 12 months, similar to the obesity group.
This reduction was maintained throughout the follow-up and
was even higher than the obesity group 69% (range 57–83) vs
59% (range 43–73%), p < 0.05 at the end follow-up (Table 2).
Changes  in  renal  function
As shown in Tables 2 and 3 and Fig. 4, renal func-
tion deteriorated signiﬁcantly during the previous period
12 months before the start of treatment with spirono-
lactone (−0.27 ± 0.6 mL/min/1.73 m2/month). After the ﬁrst
month of treatment with spironolactone, renal func-
tion showed a signiﬁcant drop (−3.2 ± 8.8 mL/min/1.73 m2
s.
 32) Patients with no obesity (n = 39) P value
14 (46.7) 0.23
37 (94.9) 0.14
33 (84.6) 0.11
23 (59) 0.76
2 (5.1) 0.00
3 (7.7) 0.022
2 (5.1) 0.84
10 (25.6) 0.60
24 (61.5) 0.72
4 (10.3) 0.06
1 (2.6) 0.88
 enzyme inhibitors; ARA, angiotensin-receptor antagonists.
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he follow-up.
In the non-obesity group, there was non signiﬁcant
mprovement between the slope of GFR drop between
he period prior to treatment with spironolactone
−4.6 ± 18.7 ml/min/year) and from the start of treatment
o the end of the follow-up (−2.3 observed ± 7.3 ml/min/year,
 .54). Twenty-three patients (59%) showed improvement in
enal function during the follow-up.
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Changes  in  blood  pressure  and  serum  potassium  levels
Blood pressure levels was signiﬁcantly reduced in both groups
during the ﬁrst month of treatment with spironolactone
(Table 2) and remained stable during the follow-up. Serum
potassium levels increased signiﬁcantly after the ﬁrst month
of treatment but remained stable during the follow in both
groups (Table 2). There was no signiﬁcant inﬂuence between
the changes in BP and GFR (r = 0.27, p = .13).
Safety  and  tolerance  of  spironolactone
During the study, there were no deaths and no onset
of advanced chronic renal failure or duplication of base-
line serum creatinine levels. Nine patients (28%) devel-
oped gynecomastia shortly after starting treatment with
spironolactone and were therefore switched to eplerenone
(25 mg/day). It is important to note that the incidence of
gynecomastia in the control group was clearly lower (5%,
p < .05) (Table 3). There were no differences in terms of
renal function and proteinuria results between the patients
who switched to eplerenone and those who  remained with
spironolactone. During the study, 2 patients (6%) discontin-
ued the treatment with AA due to persistent hyperpotassemia
(>5.5–6 mEq/L), despite the adopted therapeutic measures.
The number of patients who discontinued the treatment in
the control group was similar (2 patients, 5%). Of the 2 patients
with obesity who had to discontinue the treatment, both had
diabetes and 1 had a GFR < 60 mL/min/1.73 m2 at the start
of the study. The discontinuation of AA occurred 14 and
19 months after the start of the treatment. The 2 cases that
had to discontinue spironolactone were treated with ARA at
the start of the study.
At the end of the follow-up, 22 patients were undergoing
concomitant treatment for hyperpotassemia (12 patients with
cation exchange resins and 10 patients with low doses of thi-
azide). The mean dosage of spironolactone and eplerenone
at the end of the study was 27.7 ± 19.6 mg/24 h (12.5–100) and
37.5 ± 19.8 mg/24 h (12.5–75), respectively.
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Discussion
Our study provides clinical information on the long-term
outcome of reducing proteinuria and the changes in renal
function in a cohort of patients with obesity and with various
types of kidney diseases who  were treated with spironolac-
tone due to persistent proteinuria >1 g/d, despite treatment
with ACEIs, ARAs or their combination. As shown in Table 2
and Fig. 2, renal function showed a progressive reduction
in the 12-month period prior to treatment with spirono-
lactone. Although we observed an abrupt drop in GFR
(−3.2 ± 8.8 mL/min/1.73 m2) after the ﬁrst month of treatment,
which could lead us to reconsider discontinuing the use of the
drug, renal function improved after the ﬁrst month of treat-
ment until the end of the follow-up. The comparison of GFR
slopes during the pretreatment period (12 months prior) and
from the ﬁrst month of treatment to the end of the follow-up
showed a tendency that did not achieve statistical signif-
icance. An important aspect of our study is the extended
follow-up time, which enables us to conﬁdently assert the
beneﬁcial effect spironolactone has on the reduction of pro-
teinuria and the improvement and/or stabilization of renal
function.
Experimental and clinical studies have shown that RAAS
activity is increased in obesity and that adipose tissue,
especially visceral, synthesizes all RAAS components.13,22
Moreover, patients with obesity have high plasma aldos-
terone levels,17,23 and recent studies have shown that visceral
adipocytes can secrete various factors that increase aldos-
terone production by adrenal glands, through pathways other
than the classical renin-angiotensin pathways.24 Oxidized
fatty acids, typically found in high levels in patients with obe-
sity, can also increase aldosterone synthesis.25 This collection
of data could suggest a more  favorable effect of AAs in patients
with obesity, due to the hyperaldosteronism associated with
obesity. However, our study did not ﬁnd any difference in the
proteinuric effect, control of the blood pressure or slowing of
the decline in GFR between obese and non-obese patients.
Our study shows that the antiproteinuric effect in patients
with obesity persists without change during the follow-up,
a fairly important fact given that it could only be evaluated
over short periods of time.19,20 The antiproteinuric effect was
notably homogeneous; most of the patients showed sustained
proteinuria reductions greater than 50%, even 48 months after
the introduction of AA.
It is very interesting the behavior of the 25 diabetic patients
in this substudy. In both groups showed a signiﬁcant reduc-
tion in proteinuria (68.2%) during the follow-up (3.7 ± 2.3
to 1.2 ± 1.6 g/24 h, p < 0.05), with a clear slowing of decline
in GFR (6.2 ± 14.7 ml/min/year to 2.7 ± 6.5 ml/min/year, p .36)
since the introduction of aldosterone. These ﬁndings show us
that the early introduction of these drugs in patients with dia-
betic nephropathy could ﬁnd a beneﬁcial renoprotective effect.
Although serum potassium levels showed a signiﬁcant
increase after the introduction of spironolactone, they were
easily controlled with a low-potassium diet, cation exchange
resins or low-dose thiazide diuretics. During the study, only
2 patients (6%) discontinued the treatment with AA due to per-
sistent hyperpotassemia (>5.5–6 mEq/L), despite the adopted3  5(6):554–561
therapeutic measures. Gynecomastia is a relatively common
secondary effect in patients with obesity treated with spirono-
lactone and was observed in 28.1% of the patients, which was
higher than in the control group (5.1%, p = .007). The condition
was completely resolved by changing to eplerenone, another
AA that does not share this complication.
Although our results show a low incidence of hyper-
potassemia and other severe complications, it is important to
emphasize that careful monitoring of our patients is necessary
and that this policy should be recommended for all patients
treated with AAs, particularly those cases with mild levels of
renal failure.
Recent studies have alerted us to the risk of severe
complications (renal function impairment, hyperpotassemia
and hypotension) in patients treated with dual ACEI+ARA
blockers.26,27 We  observed no more  adverse effects in our
patients after the introduction of the AA in patients who  were
treated with ACEI+ARA when compared with the patients
treated with ACEI or ARA alone. All patients treated with dual
blockers at the start of the study (9 of 32) progressively with-
drew the ACEI or ARA during the follow-up due to better blood
pressure control and satisfactory proteinuria reduction after
the introduction of the AA. In this respect, our data suggest
that ACEI+AA or ARA+AA combinations could be an interest-
ing alternative to dual ACEI+ARA blockers.
Another fundamental issue is the beneﬁcial effect of AA
on cardiometabolic syndrome and resistant arterial hyperten-
sion in patients with obesity. There is increasing scientiﬁc
evidence that relates an excess of circulating aldosterone to
metabolic effects and endothelial function, which contribute
to the genesis of hypertension, cardiovascular disease and
nephropathy.28 Therefore, the use of AAs has clear utility in
cardiovascular prevention and blood pressure control. In our
study, we were able to observe a clear reduction in BP (8.5%),
which, coupled with the renoprotective effects, may be con-
sidered an excellent therapeutic option for this patient group.
Our study has signiﬁcant limitations, such as a small num-
ber of patients, the fact that it is not a randomized and
controlled study and a lack of biochemical measurements
for renin-aldosterone and ions in urine, which could have
veriﬁed the beneﬁcial effects of these drugs. An important
limitation of this study is that the formula used to calcu-
late the GFR-MDRD-4 is not validated in the obese population.
However, this study reproduces the standard clinical practice
with signiﬁcant ﬁdelity. For this reason, more  comparative
studies are warranted to determine whether these antipro-
teinuric and renoprotective effects of AA are shared by other
types of diuretics in the population with obesity, given that a
number of studies have shown that thiazides can induce sig-
niﬁcant reductions in proteinuria when added to ACEIs and/or
ARAs.29 Similarly, sodium restriction boosts the antiprotein-
uric response to ACEIs and ARAs,30 and the combination of
hydrochlorothiazide with a low-sodium diet increases the
response even further.31
In summary, the antiproteinuric effect and trend to slowing
progression of renal failure with AA treatment in protein-
uric nephropathies not changed by the condition of obesity.
The renoprotective effect of aldosterone antagonists should
be conﬁrmed in larger prospective trials. The rational use of
these drugs in adequate doses with close monitoring of side
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ffects can combine their antiproteinuric effect and an ade-
uate safety proﬁle.
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